ALT-100 mAb

Phase 2

TherapeuticsMD, Inc. (TXMD)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q2 '27

TXMDPhase 2$9M

ALT-100 mAb Phase 2 Est. Readout

ALT-100 mAb• Acute Respiratory Distress Syndrome (ARDS)15

Q2 2027~QConfirmed

CT.gov

00%

Competitive Landscape

0 competitors in Acute Respiratory Distress Syndrome (ARDS)

View Full Landscape

Drug Information

Target Indication

Acute Respiratory Distress Syndrome (ARDS)

Clinical Trial

NCT05938036

Last updated: 7/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

TXMD

TherapeuticsMD, Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

PegtibatinasePhase 3

Homocystinuria

DexycuPhase 3

Inflammation

ETC-1002Phase 3

Hypercholesterolemia

Human plateletsPhase 3

Cardiac Surgery

3.2 mg intranasal carbetocinPhase 3

Prader-Willi Syndrome

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts